Millie
your market intelligence analyst
Search Results
92 results
Your search is now limited to «Monoclonal Antibody Therapy» expert search.
Benzinga 10/17/2019 10:51
Despite recent improvements and approvals of medicines, a significant clinical need remains for patients with advanced HER2-positive metastatic breast cancer, according to AstraZeneca.
More from Benzinga:
Business Wire 10/17/2019 09:00
In oncology, PPD Laboratories performed the bioanalysis on five of the six ADCs currently approved by the FDA and helped develop 19 of the 20 top-selling cancer therapies of 2018.
More from Business Wire:
ClinicalTrials.gov 10/16/2019 08:29
Currently, there is no standard treatment option for CTCL, especially for advanced stages, and the optimal treatment sequence is still debated with a large variability in the therapeutic approach across countries.
More from ClinicalTrials.gov:
Translational Relevance Bendamustine and rituximab (BR) is widely accepted as a superior frontline therapy over R-CHOP in the treatment of follicular lymphoma.
More from Clinical Cancer Research - Recent Issues (abstracts):
Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
More from Middle East North Africa Financial Network (MENAFN):
GlobeNewswire 10/11/2019 10:58
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD.
More from GlobeNewswire:
PharmiWeb.com 10/10/2019 21:52
A recently innovative technology is developed to achieve a more selective and effective treatment of cancer, which converts proteins and antibodies into stable, powerful drug transporters that more accurately detect and kill tumor cells, making ADCs safer and more effective.
More from PharmiWeb.com:
PR Newswire 10/08/2019 06:45
Consider anti-TB therapy prior to initiating Olumiant in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection ...
More from PR Newswire:
Cancer Network 10/07/2019
CAR T cells directed against the B-cell maturation antigen (BCMA) have demonstrated impressive initial results, but available data suggest that most patients with initial responses eventually progress,” wrote Alfred L. Garfall, MD, of Abramson Cancer Center, and colleagues.
More from Cancer Network:
Oral Diseases 10/02/2019 05:20
Abstract. Programmed cell death‐ligand 1 (PD‐L1) is a transmembrane protein that acts as a co‐inhibitory factor in the immune response. Its receptor, programmed cell death protein 1 (PD‐1), is found on immune cells, where binding to PD‐L1 can reduce the proliferation of PD‐1‐positive cells, inhibit their cytokine secretion and induce apoptosis. PD‐L1 in immune‐privileged tissue plays a crucial role in peripheral tolerance. PD‐L1 can be overexpressed in various malignancies, including oral squamous cell carcinoma, where it can attenuate the host immune response to tumour cells and has been associated with a worse prognosis. Monoclonal antibody therapies targeting the PD‐1:PD‐L1 axis have shown initial promise, but further research is needed t.
News-Medical.net 09/30/2019 11:26
The BFAST trial included over 2,200 patients with non-small cell lung cancer (NSCLC) and without a history of prior treatment.
More from News-Medical.net:
Healio News 09/27/2019 12:23
A higher percentage of patients assigned chemotherapy received subsequent cancer therapies (49.5% vs. 29.6.
More from Healio News:
GaBI Online 09/27/2019 05:49
On 12 September 2019, the two companies signed a cooperation agreement to establish SPH-Biocad (HK), which will manufacture and market six Biocad treatments based on monoclonal antibodies (mAbs.
More from GaBI Online:
BioNewsFeeds 09/24/2019 08:42
The company plans to start testing FT596 for the treatment of B-cell lymphoma and chronic lymphocytic leukemia, either alone or in combination with CD20-targeted monoclonal antibodies.
More from BioNewsFeeds:
Estimated Drug Costs for Bone-Modifying Agents Treatment of patients with a history of cancer who are at risk for osteoporosis will often be under the purview of the primary oncology treatment team during active treatment.
More from American Society of Clinical Oncolgy (ASCO):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications